- Oggetto:
- Oggetto:
Translational medicine in severe asthma
- Oggetto:
Academic year 2022/2023
- Teacher
- Prof. Fabio Luigi Massimo Ricciardolo (Titolare del corso)
- Degree course
- Ciclo XXXV
Ciclo XXXVI
Ciclo XXXVII - Teaching period
- Da definire
- Type
- Course
- Credits/Recognition
- 1
- Delivery
- A distanza
- Language
- Inglese
- Oggetto:
Sommario del corso
- Oggetto:
Course objectives
Bronchial asthma is a complex and heterogeneous chronic inflammatory disorder of the airways with variable airflow obstruction. According to the Global Burden Disease Study, about 240 million people suffer from asthma worldwide, and in 2016 it caused 495.000 deaths. A subset of asthmatic patients (10-20%) has uncontrolled respiratory symptoms, with half of them being affected by severe asthma. Based on ATS/ERS expert panel consensus, severe asthma is defined as asthma requiring treatment with guideline suggested medications for GINA steps 4–5 asthma (high dose inhaled corticosteroid and long-acting beta-agonist or leukotriene modifier/theophylline) for the previous year or systemic corticosteroid for ≥50% of the previous year to maintain disease control. Severe asthma, despite affecting only 5-10% of asthmatics, is responsible for a large part of asthmarelated national healthcare costs.
Despite a growing number of personalized therapeutic options are becoming available for severe asthmatic patients some of them still remain unresponsive or with partly controlled disease. This is in part a consequence of the great heterogeneity of the disorder, to such a degree that it is possible to identify several clinical, biological and pathophysiological phenotypes each of them underlined by specific molecular mechanisms (endotypes), which are responsible of a highly variable response of patients to therapies. Over the last years, several studies on large cohorts were performed to identify phenotype clusters, with the aim of developing personalized therapies.
This course is focused on the description of the complexity and heterogeneity of this respiratory disorder, aiming to innovation and personalized therapy based on the principles of precision medicine.
- Oggetto:
Course delivery
Slides with power-point presentation, reviews and original articles (suggested readings).
At least 2 lessons (2 hours per lesson) and 2 meetings with students showing presentations concerning other model of precision medicine with personalized therapy (e.g. lung cancer and others).
- Oggetto:
Learning assessment methods
Final test examinations
- Oggetto:
Program
- Definition
- Diagnosis
- Pathophysiology
- Phenotypes
- Endotypes
- Pharmacological Therapy and Biologics
Suggested readings and bibliography
- Oggetto:
.
- Oggetto:
Note
Mandatory Course for XXXV/XXXVI/XXXVII Cycle Students
- Oggetto:
